Related Experiment Video

Updated: May 12, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

ANTIPHOSPHOLIPID SYNDROME AS A MODIFIER OF CLINICAL PHENOTYPES IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: A

N Archaia1, V Chumburidze2, N Kakauridze3

  • 11Faculty of Medicine, Ivane Javakhishvili Tbilisi State University, Georgia.

Georgian Medical News
|May 10, 2026
PubMed

Insights

Antiphospholipid syndrome (APS) significantly increases venous and central nervous system thrombosis risk in atherosclerotic cardiovascular disease (ASCVD) patients. APS modifies ASCVD by promoting thrombosis rather than causing atherosclerosis.

Area of Science:

  • Immunology
  • Cardiology
  • Hematology

Background:

  • Antiphospholipid syndrome (APS) is an autoimmune disorder linked to thrombosis.
  • The role of APS in atherosclerotic cardiovascular disease (ASCVD) phenotypes is not fully understood.

Purpose of the Study:

  • To investigate the association between APS and clinical, thrombotic, and laboratory features in ASCVD patients.

Main Methods:

  • A single-center case-control study included 355 ASCVD patients (92 with APS, 92 without).
  • Evaluated clinical characteristics, vascular involvement, risk factors, coagulation parameters, and antiphospholipid antibodies.
  • Utilized correlation and multivariable regression analyses.

Main Results:

  • APS prevalence was 25.9% in ASCVD patients.
  • APS-positive patients had higher rates of venous thrombosis (OR 4.02) and CNS arterial thrombosis (OR 2.40).
  • Lupus anticoagulant was the most common antibody; IgG antibodies correlated with activated partial thromboplastin time.

Conclusions:

  • APS is linked to a distinct thrombotic phenotype in ASCVD, including increased venous and cerebrovascular thrombosis.
  • Findings suggest APS acts as an immunothrombotic modifier of ASCVD, influencing atherosclerosis development.
Abstract

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...